Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00879190
Recruitment Status : Completed
First Posted : April 9, 2009
Results First Posted : March 15, 2017
Last Update Posted : May 18, 2018
Information provided by (Responsible Party):
Natali Aziz, Stanford University

April 7, 2009
April 9, 2009
October 31, 2016
March 15, 2017
May 18, 2018
May 2009
June 2012   (Final data collection date for primary outcome measure)
Treatment Success Defined as Resolution of Fever by 24 Hours Postpartum [ Time Frame: Up to 24 hours after delivery ]
Proportion of patients in each arm experiencing treatment success defined as resolution of fever by 24 hours postpartum
Proportion of patients in each arm experiencing treatment failure as indicated by resolution of maternal infection
Complete list of historical versions of study NCT00879190 on Archive Site
  • Composite Maternal Morbidity [ Time Frame: Up to 6 weeks after delivery ]
    Composite of maternal postpartum morbidity defined as any of the following outcomes: endometritis, clinical sepsis, pneumonia, blood transfusion or ileus.
  • Neonatal Clinical Sepsis (Early Onset) [ Time Frame: Up to 6 weeks after delivery ]
  • Cost
  • Maternal adverse effects including side effects, labor abnormalities, type of delivery, blood loss, post partum infectious complication
  • Neonatal adverse outcomes
Not Provided
Not Provided
Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis
Comparison of Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Intrapartum Chorioamnionitis: a Randomized Controlled Trial
Chorioamnionitis is an infection of the placenta and amniotic membranes (bag of waters) surrounding the baby inside of a pregnant woman prior to delivery. This infection is somewhat common and is routinely treated with antibiotics given to the mother both before and after the baby is born. Currently it is not known what is the best choice of antibiotics to treat this type of infection, but commonly used treatments include Unasyn (ampicillin/sulbactam) or ampicillin/gentamicin. We plan to compare these two different antibiotic regimens to see if one is better than the other at treating and preventing bad outcomes from chorioamnionitis in women and babies.
Patients who meet inclusion criteria will be approached upon admission to Labor and Delivery. A study staff member will describe the study and offer participation. If a patient agrees to participate, she will sign research protocol and HIPAA consent forms and receive a copy of these forms. The patient's chart will be flagged, indicating that she is a study participant. The patient's prenatal care and labor and delivery will be managed by her physician per standard of care at the physician's discretion, including routine intrapartum treatment of Group B streptococcus (GBS) colonization using ampicillin. When a participating patient is diagnosed with chorioamnionitis, she will be randomized in a blinded fashion to Arm 1 (Unasyn) or Arm 2 (ampicillin/gentamicin). She will be treated as per standard of care with tylenol, intravenous fluids, and her labor managed per physician discretion. From the time of diagnosis of chorioamnionitis until determination of treatment success or failure in the postpartum period, the patient will receive intravenous antibiotics per the protocol arm to which they have been assigned. If a patient has already been receiving ampicillin for GBS, the ampicillin will be discontinued when the study drugs are initiated. In arm 1, the study drugs will consist of Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours. In arm 2, the study drugs will consist of gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2gm intravenously every 6 hours. For all patients, clindamycin will be given intravenously at the time of clamping of the umbilical cord in the event of a cesarean delivery, and continued as part of the antibiotic regimen as per standard of care for cesarean section in the setting of chorioamnionitis. With the exception of the saline placebo doses, both the Unasyn regimen and the ampicillin/gentamicin regimen are efficacious and widely utilized regimens for the treatment of intrapartum chorioamnionitis, and do not represent a deviation from standard of care. After delivery, if the patient experiences a treatment failure as defined below, her medical care will be managed at the discretion of the attending physician as per standard of care, and her antibiotic regimen will be unblinded. After delivery, prior to discharge from the hospital, the patient will be asked to answer a short questionnaire enquiring about side effects experienced during treatment for chorioamnionitis. The patient may receive a phone call within 14 days of delivery to assess whether she has received treatment for postpartum complications at an outside institution after discharge from the hospital.
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: Unasyn
    Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
  • Drug: Ampicillin/gentamicin
    Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
  • Active Comparator: Unasyn (ampicillin/sulbactam)
    Intervention: Drug: Unasyn
  • Active Comparator: Ampicillin/gentamicin
    Intervention: Drug: Ampicillin/gentamicin
Greenberg, Mara et al. Comparison of ampicillin/sulbactam versus ampicillin/gentamicin for treatment of intrapartum chorioamnionitis: a randomized controlled trial. American Journal of Obstetrics & Gynecology , Volume 212 , Issue 1 , S145

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2012
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Pregnant women in labor or undergoing induction of labor
  2. Greater than or equal to 18 years of age
  3. Diagnosed with chorioamnionitis as defined by maternal temperature > or = 38.0 degrees Centigrade plus at least one of the following: maternal tachycardia (heart rate >110), fetal tachycardia (fetal heart rate baseline >160), purulent amniotic fluid, uterine tenderness.

Exclusion Criteria:

  1. Allergy or adverse reaction to penicillin or ampicillin, gentamicin, or sulbactam
  2. Having received antibiotics for the treatment of preterm premature rupture of membranes or other condition within the last 7 days
  3. Acute or chronic renal disease or insufficiency (creatinine >1.0)
  4. Hearing loss
  5. Major fetal congenital anomalies or intrauterine fetal demise
  6. Neutropenia
  7. HIV
  8. Myasthenia gravis or other neuromuscular disorder
Sexes Eligible for Study: Female
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
15562 ( Other Identifier: Stanford University Research Compliance Office )
Not Provided
Plan to Share IPD: No
Natali Aziz, Stanford University
Stanford University
Not Provided
Principal Investigator: Natali Aziz, MD Stanford University
Stanford University
April 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP